Form 4: Cytokinetics EVP Fady Ibraham Malik Sells Shares to Cover Restricted Stock Unit Vesting
SEC Form 4 Filing
Fady Ibraham Malik, EVP of Research & Development at Cytokinetics Inc, sold 4,389 shares of common stock on March 17, 2025, to cover taxes associated with the vesting of restricted stock units.
Summary
- On March 17, 2025, Fady Ibraham Malik, the EVP of Research & Development at Cytokinetics Inc, sold 4,389 shares of the company's common stock.
- The sale was executed at a price of $44.38 per share.
- This transaction was a 'sell to cover' transaction related to the vesting of restricted stock units.
- Following the transaction, Malik directly owns 101,005 shares of Cytokinetics Inc.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a routine transaction related to executive compensation and doesn't necessarily indicate a positive or negative outlook for the company.
Industry Context
This is a routine transaction for executives who receive stock-based compensation. It is common practice to sell a portion of the shares to cover the tax obligations arising from the vesting of restricted stock units.
Key Dates
| Date | Description |
|---|---|
| 03/17/2025 | Date of stock sale transaction. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.